Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
26 Outubro 2009 - 10:52AM
PR Newswire (US)
BALTIMORE, Oct. 26 /PRNewswire-FirstCall/ -- Champions
Biotechnology, Inc. (OTC:CSBR) (BULLETIN BOARD: CSBR) , a company
with a predictive preclinical platform aimed at accelerating the
development and enhancing the value of oncology drugs, has
established an agreement with Ortho Biotech Oncology Research &
Development, a Division of Janssen Pharmaceutica NV, for the
evaluation of a novel preclinical oncology therapeutic in
Champions' Biomerk Tumorgraft(TM) platform. "We are excited to
expand this ongoing collaboration in the development of innovative
therapeutics in oncology," said Doug Burkett, Ph.D., President of
Champions Biotechnology, Inc. "We continue to grow our customer
base and revenues within our Preclinical eValuation business. Our
Biomerk Tumorgraft models offer a more predictive preclinical
platform to enhance and accelerate oncology drug development.
Evaluations in our Tumorgraft models are expected to enable the
identification of the most promising development path by focusing
on indication, drug combinations, target patient populations and
biomarker discovery." For more information regarding Champions
Biotechnology's growing business and recent news, please visit
http://www.championsbiotechnology.com/. About Champions
Biotechnology, Inc. Champions Biotechnology, Inc. is engaged in the
development of advanced preclinical platforms and tumor specific
data to enhance and accelerate the value of oncology drugs. The
Company's Preclinical Platform is a novel approach based upon the
implantation of primary human tumors in immune deficient mice
followed by propagation of the resulting engraftments (Biomerk
Tumorgrafts(TM)) in a manner that preserves the biological
characteristics of the original human tumor. Early studies suggest
that unlike traditional xenografts, these Tumorgrafts closely
reflect human cancer biology and their response to drugs is
predictive of clinical outcomes in cancer patients. Champions
Biotechnology leverages its preclinical platform to evaluate drug
candidates and to develop a portfolio of novel therapeutic
candidates. As drugs progress through early stage development, the
Company plans to sell, partner or license them to pharmaceutical
and/or biotechnology companies, as appropriate. The Company also
offers its predictive preclinical platform and tumor specific data
to physicians for personalized patient care and to companies for
evaluation of oncology drugs in models that integrate prognostic
testing with biomarker discovery.
http://www.championsbiotechnology.com/http://www.personalizedcancertreatment.com/
This press release contains "forward-looking statements" (within
the meaning of the Private Securities Litigation Act of 1995) that
inherently involve risk and uncertainties. Champions Biotechnology
generally uses words such as "believe," "may," "could," "will,"
"intend," "expect," "anticipate," "plan," and similar expressions
to identify forward-looking statements. One should not place undue
reliance on these forward-looking statements. The Company's actual
results could differ materially from those anticipated in the
forward-looking statements for many unforeseen factors. See
Champions Biotechnology's Form 10-K for the fiscal year ended April
30, 2009 for a discussion of such risks, uncertainties and other
factors. Although the Company believes the expectations reflected
in the forward-looking statements are reasonable, they relate only
to events as of the date on which the statements are made, and
Champions Biotechnology's future results, levels of activity,
performance or achievements may not meet these expectations. The
Company does not intend to update any of the forward-looking
statements after the date of this press release to conform these
statements to actual results or to changes in Champions
Biotechnology's expectations, except as required by law. CONTACT:
The Investor Relations Group, Inc. James Carbonara +1-212-825-3210
DATASOURCE: Champions Biotechnology, Inc. CONTACT: James Carbonara,
The Investor Relations Group, Inc., +1-212-825-3210 Web Site:
http://championsbiotechnology.com/
Copyright